ORBIMED ADVISORS LLC
ORBIMED ADVISORS LLC has made 2 open-market purchases worth $36.1M since Sep 23, 2026, in 2 companies. The latest: $16.1M of ADRX, filed Sep 30, 2026, scored 46 out of 100.
Director, ADARx Pharmaceuticals, Inc. Director, Electra Therapeutics, Inc.
Follow ORBIMED ADVISORS LLC, freeOpen the live feed
A free account gets an alert the minute a new buy or sale is filed.
Purchases
| Filed | Stock | Stake | Score | Bought | 1 week | 1 month |
|---|---|---|---|---|---|---|
| Sep 30 Form 4 (opens sec.gov) |
ADRXADARx Pharmaceuticals, Inc. · DirectorDirector · 5 insiders buying | 46 | $16.1M 950,000 at $17.00 |
−9.5% | waiting | |
| Sep 23 Form 4 (opens sec.gov) |
ETRAElectra Therapeutics, Inc. · DirectorDirector · 2 insiders buying | +314% stake | 54 | $20.0M 1,333,333 at $15.00 |
−9.6% | −29.2% |
Track record (hypothetical): a week after the filing, these buys averaged −9.6% (0% up, 2 measured); a month after, −29.2% (0% up, 1 measured).
Questions
What stock has ORBIMED ADVISORS LLC bought?
ADRX (ADARx Pharmaceuticals, Inc.), ETRA (Electra Therapeutics, Inc.), all on the open market and reported on SEC Form 4.
When did ORBIMED ADVISORS LLC last buy?
Sep 30, 2026: 950,000 shares of ADRX at $17.00, $16.1M in all (Form 4 (opens sec.gov)).
Has ORBIMED ADVISORS LLC filed a notice of a planned sale?
Not in the filings on record. A Form 144 is the notice an insider must file before selling restricted or control shares, and it lands on EDGAR before the sale is reported.
Is ORBIMED ADVISORS LLC a routine or an opportunistic buyer?
There isn't enough history to say yet.
Data as of Sep 30, 2026, from SEC EDGAR Form 4 filings: open-market purchases (code P) of $25,000 or more, and open-market sales. Every row links to its filing. Scores summarise what a filing says (how the score works); outcomes are hypothetical, from the first close after the filing, and past results don't predict future ones. Disclaimer